{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:49:14Z","timestamp":1769550554260,"version":"3.49.0"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","award":["WI194340"],"award-info":[{"award-number":["WI194340"]}],"id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0196559","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T17:50:32Z","timestamp":1525283432000},"page":"e0196559","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Abrogation of transforming growth factor-\u03b2-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib)"],"prefix":"10.1371","volume":"13","author":[{"given":"Peter J.","family":"Wermuth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5213-1203","authenticated-orcid":true,"given":"Sergio A.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7113-8_1","article-title":"Human fibrotic diseases: current challenges in fibrosis research","volume":"1627","author":"J Rosenbloom","year":"2017","journal-title":"Meth Mol Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbadis.2012.12.007","article-title":"Strategies for Antifibrotic Therapies","volume":"1832","author":"J Rosenbloom","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.7326\/0003-4819-152-3-201002020-00007","article-title":"Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies","volume":"152","author":"J Rosenbloom","year":"2010","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"CP Denton","year":"2017","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"J Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2005.08.002","article-title":"Description of 12 cases of Nephrogenic Fibrosing Dermopathy and review of the literature","volume":"35","author":"FA Mendoza","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI60323","article-title":"Pulmonary fibrosis: patterns and perpetrators","volume":"122","author":"PW Noble","year":"2012","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI31487","article-title":"Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases","volume":"117","author":"TA Wynn","year":"2007","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/157339710793205611","article-title":"Role of growth factors in the pathogenesis of tissue fibrosis in Systemic Sclerosis","volume":"6","author":"SA Jimenez","year":"2010","journal-title":"Curr Rheumatol Rev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"C216","DOI":"10.1152\/ajpcell.00328.2012","article-title":"Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis","volume":"304","author":"M Zeisberg","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis-a common pathway to organ injury and failure","volume":"372","author":"DC Rockey","year":"2015","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","article-title":"The myofibroblast: one function, multiple origins","volume":"170","author":"B Hinz","year":"2007","journal-title":"Am J Pathol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.biocel.2006.11.005","article-title":"Fibroblasts and myofibroblasts: their source, function and role in disease","volume":"39","author":"RJ McAnulty","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology: paradigms for connective tissue remodeling","volume":"180","author":"B Hinz","year":"2012","journal-title":"Am J Pathol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrneph.2014.246","article-title":"Diverse origins of the myofibroblast-implications for kidney fibrosis","volume":"11","author":"LL Falke","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1042\/bj2470597","article-title":"Transforming growth factor-\u03b2 (TGF\u03b2) causes a persistent increase in steady state levels of Type I and Type III collagens and fibronectin mRNAs in normal human dermal fibroblasts","volume":"247","author":"J Varga","year":"1987","journal-title":"Biochem J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor \u03b2\u2014at the centre of systemic sclerosis","volume":"10","author":"R Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"ref18","first-page":"2373","article-title":"TGF\u03b2 signaling and the control of myofibroblast differentiation: Implications for chronic inflammatory disorders","volume":"429","author":"JM Carthy","year":"2017","journal-title":"J Cell Physiol"},{"issue":"Suppl 5","key":"ref19","doi-asserted-by":"crossref","first-page":"v2","DOI":"10.1093\/rheumatology\/ken265","article-title":"Role of PDGF in fibrotic diseases and systemic sclerosis","volume":"47","author":"M Trojanowska","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2741\/s22","article-title":"Transforming growth factor-beta in systemic sclerosis (scleroderma)","volume":"1","author":"J Varga","year":"2009","journal-title":"Front Biosci (Schol Ed)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"20172","DOI":"10.1016\/S0021-9258(17)32142-7","article-title":"Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-beta","volume":"269","author":"H Yamashita","year":"1994","journal-title":"J Biol Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/370341a0","article-title":"Mechanism of activation of the TGF-beta receptor","volume":"370","author":"JL Wrana","year":"1994","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1093\/emboj\/17.11.3091","article-title":"Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene","volume":"17","author":"S Dennler","year":"1998","journal-title":"EMBO J"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1093\/emboj\/17.14.4056","article-title":"Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine\/threonine kinase receptors","volume":"17","author":"M Kawabata","year":"1998","journal-title":"EMBO J"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0092-8674(00)81696-7","article-title":"Smads: transcriptional activators of TGF-beta responses","volume":"95","author":"R Derynck","year":"1998","journal-title":"Cell"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1097-2765(02)00585-3","article-title":"Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity","volume":"10","author":"GJ Inman","year":"2002","journal-title":"Mol Cell"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/35087019","article-title":"TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation","volume":"3","author":"R Perlman","year":"2001","journal-title":"Nat Cell Biol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1093\/emboj\/cdg440","article-title":"A role for MEK kinase 1 in TGF-beta\/activing-induced epithelium movement and embryonic eyelid closure","volume":"22","author":"L Zhang","year":"2003","journal-title":"EMBO J"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1091\/mbc.12.1.27","article-title":"Transforming growth factor-beta 1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism","volume":"12","author":"NA Bhowmick","year":"2001","journal-title":"Mol Cell Biol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/1529-0131(200102)44:2<474::AID-ANR67>3.0.CO;2-#","article-title":"Blockade of endogenous transforming growth factor \u03b2 signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor \u03b2 receptors","volume":"44","author":"H Ihn","year":"2001","journal-title":"Arthritis Rheum"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1523-1747.1998.00073.x","article-title":"Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype","volume":"110","author":"T Kawakami","year":"1998","journal-title":"J Invest Dermatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/art.10333","article-title":"Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts","volume":"46","author":"A Leask","year":"2002","journal-title":"Arthritis Rheum"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.1074\/jbc.M010149200","article-title":"CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling","volume":"276","author":"A Holmes","year":"2001","journal-title":"J Biol Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/mp.54.3.180","article-title":"The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts","volume":"54","author":"A Leask","year":"2001","journal-title":"Mol Pathol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1074\/jbc.M611742200","article-title":"Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1\/2 pathways","volume":"282","author":"J Pannu","year":"2007","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/art.11157","article-title":"Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts","volume":"48","author":"Y Mori","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0002-9440(10)63289-0","article-title":"Targeted disruption of TGF-beta\/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma","volume":"165","author":"G Lakos","year":"2004","journal-title":"Am J Pathol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/mol.105.017483","article-title":"Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression","volume":"69","author":"M Jinnin","year":"2006","journal-title":"Mol Pharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/mol.62.1.58","article-title":"Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542","volume":"62","author":"NJ Laping","year":"2002","journal-title":"Mol Pharmacol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signaling","volume":"74","author":"C Beyer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1523-1747.2002.01719.x","article-title":"Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts","volume":"118","author":"M Sato","year":"2002","journal-title":"J Invest Dermatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"CP Denton","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ophtha.2007.03.050","article-title":"A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first time trabeculectomy","volume":"114","author":"P Khaw","year":"2007","journal-title":"Ophthalmology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"LM Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.23436","article-title":"Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis","volume":"58","author":"C Skhirtladze","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1002\/art.30545","article-title":"Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo vadis?","volume":"63","author":"FA Mendoza","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/BOR.0b013e32833f1105","article-title":"Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis","volume":"22","author":"JK Gordon","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 5","key":"ref48","doi-asserted-by":"crossref","first-page":"v10","DOI":"10.1093\/rheumatology\/ken276","article-title":"Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis","volume":"47","author":"JH Distler","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molimm.2004.04.010","article-title":"Src-family kinases: rheostats of immune cell signaling","volume":"41","author":"CA Lowell","year":"2004","journal-title":"Mol Immunol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"L129","DOI":"10.1152\/ajplung.00261.2005","article-title":"Src protein tyrosine kinase family and acute inflammatory responses","volume":"291","author":"D Okutani","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbamcr.2005.03.004","article-title":"Redox regulation of platelet-derived growth-factor-receptor: role of NADPH-oxidase and c-Src tyrosine kinase","volume":"1745","author":"S Catarzi","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"C1361","DOI":"10.1152\/ajpcell.00370.2006","article-title":"TGF-beta-regulated collagen type I accumulation: role of Src-based signals","volume":"292","author":"R Mishra","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"12384","DOI":"10.1074\/jbc.M208544200","article-title":"Myofibroblast differentiation by transforming growth factor-beta 1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase","volume":"278","author":"VJ Thannickal","year":"2003","journal-title":"J Biol Chem"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.jid.5700975","article-title":"TGF-beta1 slows the growth of pathogenic myofibroblasts through a mechanism requiring the focal adhesion protein, Hic-5","volume":"128","author":"G Dabiri","year":"2008","journal-title":"J Invest Dermatol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1242\/jcs.170589","article-title":"Hic5 is required for myofibroblast differentiation by regulating mechanically dependent MRTF-A nuclear accumulation","volume":"129","author":"SD Varney","year":"2016","journal-title":"J Cell Sci"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1124\/jpet.114.213520","article-title":"Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor\/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury","volume":"349","author":"AJ Haak","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"e0126015","DOI":"10.1371\/journal.pone.0126015","article-title":"A role of myocardin-related transcription factor-A (MRTF-A) in scleroderma related fibrosis","volume":"10","author":"X Shiwen","year":"2015","journal-title":"PLoS One"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/rheumatology\/kes234","article-title":"Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblast","volume":"51","author":"X Shi-wen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.0022-202X.2005.23701.x","article-title":"Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts","volume":"124","author":"Y Mimura","year":"2005","journal-title":"J Invest Dermatol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"JH Distler","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/onc.2008.479","article-title":"A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate","volume":"28","author":"S Bhattacharyya","year":"2009","journal-title":"Oncogene"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/09553002.2013.741281","article-title":"Inhibition of radiation-induced skin fibrosis with imatinib","volume":"89","author":"JA Horton","year":"2013","journal-title":"Int J Radiat Biol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"CE Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-2370com","article-title":"Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo","volume":"19","author":"S Wang","year":"2005","journal-title":"FASEB J"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/ken369","article-title":"A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide","volume":"48","author":"I Sabnani","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/rheumatology\/ken104","article-title":"Imatinib for the treatment of refractory, diffuse systemic sclerosis","volume":"47","author":"PP Sfikakis","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/art.23694","article-title":"Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease","volume":"58","author":"JH Distler","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1002\/art.23696","article-title":"Imatinib mesylate treatment of nephrogenic systemic fibrosis","volume":"58","author":"J Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","article-title":"Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results","volume":"181","author":"CE Daniels","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"A Akhmetshina","year":"2008","journal-title":"FASEB J"},{"key":"ref71","first-page":"375","article-title":"SKI-606, a 4-anilo-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"JM Golas","year":"2003","journal-title":"Cancer Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"M Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1586\/era.12.84","article-title":"Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia","volume":"12","author":"V Keller","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-07-1269","article-title":"Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases","volume":"13","author":"P Mathew","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/sj.bjc.6604706","article-title":"Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer","volume":"99","author":"P Mathew","year":"2008","journal-title":"Br J Cancer"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"HM Kantarjian","year":"2014","journal-title":"Blood"},{"key":"ref77","first-page":"48","article-title":"Antifibrotic effects of the tyrosine kinase inhibitor, Bosutinib, on cultured normal and Systemic Sclerosis dermal fibroblasts. Abstracts from the 4th Systemic Sclerosis World Congress (Abstract Number P.020)","volume":"1","author":"S Piera-Velazquez","year":"2016","journal-title":"Journal of Scleroderma and Related Disorders"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.22328","article-title":"Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma","volume":"56","author":"S Sonnylal","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/BOR.0b013e32833130c1","article-title":"Animal models of scleroderma: lessons from transgenic and knockout mice","volume":"21","author":"EC Derrett-Smith","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.0022-202X.2004.23494.x","article-title":"A role for the androgen receptor in collagen content of the skin","volume":"123","author":"MS Markova","year":"2004","journal-title":"J Invest Dermatol"},{"key":"ref81","first-page":"436053","article-title":"Collagen content in skin and internal organs of the tight skin mouse: an animal model of scleroderma","author":"J Manne","year":"2013","journal-title":"Biochem Res Int"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0009-8981(67)90167-2","article-title":"Determination of hydroxyproline","volume":"18","author":"H Stegemann","year":"1967","journal-title":"Clin Chim Acta"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0009-8981(80)90192-8","article-title":"Modified assay for determination of hydroxyproline in a tissue hydrolysate","volume":"104","author":"CA Edwards","year":"1980","journal-title":"Clin Chim Acta"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.24471","article-title":"Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents","volume":"60","author":"PJ Wermuth","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/art.39421","article-title":"Endothelial cells expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic sclerosis-associated interstitial lung disease","volume":"68","author":"FA Mendoza","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/OARRR.S50009","article-title":"Animal models of systemic sclerosis: their utility and limitations","volume":"6","author":"CM Artlett","year":"2014","journal-title":"Open Access Rheumatol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4939-0404-4_11","article-title":"Mouse model of experimental dermal fibrosis: the bleomycin-induced dermal fibrosis","volume":"1142","author":"J Avouac","year":"2014","journal-title":"Methods Mol Biol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0196559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T16:07:57Z","timestamp":1661098077000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0196559"}},"subtitle":[],"editor":[{"given":"Donald","family":"Gullberg","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":87,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0196559","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]}}}